Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compared with pioglitazone for glycemic control, and superio...
| Principais autores: | , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Wiley
2021-07-01
|
| coleção: | Journal of Diabetes Investigation |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1111/jdi.13457 |
| _version_ | 1831555751282212864 |
|---|---|
| author | Kyu Yong Cho Akinobu Nakamura Kazuno Omori Takahiro Takase Aika Miya Kohei Yamamoto Hiroshi Nomoto Hiraku Kameda Shinji Taneda Yoshio Kurihara Shin Aoki Tatsuya Atsumi Hideaki Miyoshi |
| author_facet | Kyu Yong Cho Akinobu Nakamura Kazuno Omori Takahiro Takase Aika Miya Kohei Yamamoto Hiroshi Nomoto Hiraku Kameda Shinji Taneda Yoshio Kurihara Shin Aoki Tatsuya Atsumi Hideaki Miyoshi |
| author_sort | Kyu Yong Cho |
| collection | DOAJ |
| description | Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compared with pioglitazone for glycemic control, and superiority regarding weight reduction in patients with type 2 diabetes. We carried out a secondary analysis for the favorable effects of sodium–glucose cotransporter inhibitors for NAFLD. Materials and Methods In this multicenter, open‐label, prospective, randomized, parallel‐group comparison trial, patients taking pioglitazone for ≥12 weeks were randomly switched to dapagliflozin or continued pioglitazone for a further 24 weeks. The fatty liver index (FLI), consisting of body mass index, triglycerides, waist circumference and γ‐glutamyl transpeptidase, was used for the evaluation of NAFLD. Results A total of 53 participants with NAFLD (27 dapagliflozin; 26 pioglitazone) were included in this analysis. FLI decreased significantly in the dapagliflozin group (48.7 ± 23.4 to 42.1 ± 23.9) compared with the pioglitazone group (49.0 ± 26.1 to 51.1 ± 25.8; P < 0.01). Multiple linear regression analysis showed that the changes in FLI had a significantly positive correlation with changes in glycated hemoglobin (P = 0.03) and insulin level (P < 0.01) in the dapagliflozin group. Conclusion Dapagliflozin might be more beneficial than pioglitazone in patients with NAFLD. Improvements in FLI would be closely related to glycemic control. |
| first_indexed | 2024-12-17T04:24:30Z |
| format | Article |
| id | doaj.art-ffadb1ffdf4c4d3d9a134f5dc545c62d |
| institution | Directory Open Access Journal |
| issn | 2040-1116 2040-1124 |
| language | English |
| last_indexed | 2024-12-17T04:24:30Z |
| publishDate | 2021-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj.art-ffadb1ffdf4c4d3d9a134f5dc545c62d2022-12-21T22:03:44ZengWileyJournal of Diabetes Investigation2040-11162040-11242021-07-011271272127710.1111/jdi.13457Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazoneKyu Yong Cho0Akinobu Nakamura1Kazuno Omori2Takahiro Takase3Aika Miya4Kohei Yamamoto5Hiroshi Nomoto6Hiraku Kameda7Shinji Taneda8Yoshio Kurihara9Shin Aoki10Tatsuya Atsumi11Hideaki Miyoshi12Department of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDiabetes Center Manda Memorial Hospital Sapporo JapanKurihara Clinic Sapporo JapanAoki Clinic Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanDepartment of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo JapanAbstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compared with pioglitazone for glycemic control, and superiority regarding weight reduction in patients with type 2 diabetes. We carried out a secondary analysis for the favorable effects of sodium–glucose cotransporter inhibitors for NAFLD. Materials and Methods In this multicenter, open‐label, prospective, randomized, parallel‐group comparison trial, patients taking pioglitazone for ≥12 weeks were randomly switched to dapagliflozin or continued pioglitazone for a further 24 weeks. The fatty liver index (FLI), consisting of body mass index, triglycerides, waist circumference and γ‐glutamyl transpeptidase, was used for the evaluation of NAFLD. Results A total of 53 participants with NAFLD (27 dapagliflozin; 26 pioglitazone) were included in this analysis. FLI decreased significantly in the dapagliflozin group (48.7 ± 23.4 to 42.1 ± 23.9) compared with the pioglitazone group (49.0 ± 26.1 to 51.1 ± 25.8; P < 0.01). Multiple linear regression analysis showed that the changes in FLI had a significantly positive correlation with changes in glycated hemoglobin (P = 0.03) and insulin level (P < 0.01) in the dapagliflozin group. Conclusion Dapagliflozin might be more beneficial than pioglitazone in patients with NAFLD. Improvements in FLI would be closely related to glycemic control.https://doi.org/10.1111/jdi.13457Fatty liverSodium–glucose cotransporter 2 inhibitorType 2 diabetes |
| spellingShingle | Kyu Yong Cho Akinobu Nakamura Kazuno Omori Takahiro Takase Aika Miya Kohei Yamamoto Hiroshi Nomoto Hiraku Kameda Shinji Taneda Yoshio Kurihara Shin Aoki Tatsuya Atsumi Hideaki Miyoshi Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone Journal of Diabetes Investigation Fatty liver Sodium–glucose cotransporter 2 inhibitor Type 2 diabetes |
| title | Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone |
| title_full | Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone |
| title_fullStr | Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone |
| title_full_unstemmed | Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone |
| title_short | Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone |
| title_sort | favorable effect of sodium glucose cotransporter 2 inhibitor dapagliflozin on non alcoholic fatty liver disease compared with pioglitazone |
| topic | Fatty liver Sodium–glucose cotransporter 2 inhibitor Type 2 diabetes |
| url | https://doi.org/10.1111/jdi.13457 |
| work_keys_str_mv | AT kyuyongcho favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT akinobunakamura favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT kazunoomori favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT takahirotakase favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT aikamiya favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT koheiyamamoto favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT hiroshinomoto favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT hirakukameda favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT shinjitaneda favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT yoshiokurihara favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT shinaoki favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT tatsuyaatsumi favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone AT hideakimiyoshi favorableeffectofsodiumglucosecotransporter2inhibitordapagliflozinonnonalcoholicfattyliverdiseasecomparedwithpioglitazone |